Refine your search
Collections
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Solanki, Roshni
- New Approaches in the Treatment of Inflammatory Bowel Disease
Abstract Views :306 |
PDF Views:4
Authors
Affiliations
1 Dept. of Pharmacology, Faculty of Pharmacy, DDU, Nadiad-387001, IN
1 Dept. of Pharmacology, Faculty of Pharmacy, DDU, Nadiad-387001, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 2, No 3 (2010), Pagination: 228-232Abstract
Inflammatory bowel disease (IBD) commonly refers to ulcerative colitis (UC) and Crohn disease (CD), which are chronic inflammatory diseases of the GI tract of unknown etiology. This inflammatory response is most likely made possible by defects in both the mucosal immune system and the barrier function of the intestinal epithelium. Many conventional treatments are used to inhibit inflammation and suppress the immunological response like 5-amino salicylic acid, Corticosteroids, antibiotics etc. Recently biological therapy involving specific molecular players which are specialized proteins interfering with the body's inflammatory response are targeted for treatment of IBD Promising targets include tumor necrosis factor TNF-alpha, interleukins, adhesion molecules, colony-stimulating factors, and others. Elevation of cAMP by PDE4 inhibition and selective COX-2 inhibition is a new option to treat inflammatory bowel disease.Keywords
Inflammatory Bowel Disease, TNF-Alpha.
References
- Sartor RB. (1995) Current concepts of the etiology and pathogenesis of Ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am.1995, 24: 475-485.
- Giorgos Bamias, MD; Mark R. Nyce, MD; Sarah A. De La Rue, PhD; and Fabio Cominelli, MD, PhD. (20 December 2005); Volume 143 Issue 12|Pages 895-904.
- Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut. 2000, 46:336-343.
- Sandler RS. Epidemiology of inflammation bowel disease. In: Targan SR, Shanahan F, eds.(1994). Inflammatory Bowel Disease: From Bench to Bedside. Baltimore: Williams and Wilkins, 1994, 330-335.
- Moum B, Vatn MH, Ekbom A, et al. Incidence of Crohn's disease in four counties in southeastern Norway, 1990-93. A prospective population-based study. The Inflammatory Bowel South-Eastern Norway (IBSEN) Study Group of Gastroenterologists. Scand J Gastroenterol. 1996, 31:355-361.
- Niv Y, Abuksis G, Fraser GM.(2000). Epidemiology of ulcerative colitis in Israel: a survey of Israeli kibbutz settlements. Am J Gastroenterol. 2000, 95:693-698.
- Sandborn WJ, Tremaine WJ, Offord KP, et al. Transdermal nicotine for mildly to moderately active ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997, 126:364-371.
- Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut. 2000, 46:336-343.
- Evans JM, McMahon AD, Murray FE, McDevitt DG, MacDonald TM. Nonsteroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut. 1997, 40:619-622.
- Lindberg E, Tysk C, Andersson K, Jarnerot G. Smoking and inflammatory bowel disease: a case control study. Gut. 1988, 29:352-357.
- Sandborn WJ, Tremaine WJ, Offord KP, et al. Transdermal nicotine for mildly to moderately active ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997, 126:364-371.
- Kathleen A. Head, ND and Julie S. Jurenka, MT (ASCP), Alternative Medicine Review Inflammatory bowel disease part-I: ulcerative colitis-pahophysiology and conventional and alternative treatment options. 2003, Volume 8, number 3, p.247-283.
- Barbara A. Hendrickson, Ranjana Gokhale, and Judy H. Cho, Clinical Aspects and Pathophysiology of Inflammatory Bowel Disease. Clinical Microbiology Reviews, January 2002, Vol. 15, No. 1 p. 79-94.
- Lashner BA. Recommendations for colorectal cancer screening in ulcerative colitis: a review of research from a single university-based surveillance program. Am J Gastroenterol. 1992, 87:168-75.
- Lindberg E, Tysk C, Andersson K, Jarnerot G. Smoking and inflammatory bowel disease: a case control study. Gut. 1988, 29:352-357.
- Sandborn WJ, Tremaine WJ, Offord KP, et al. Transdermal nicotine for mildly to moderately active ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997, 126:364-371.
- Kathleen A. Head, ND and Julie S. Jurenka, MT (ASCP), Alternative Medicine Review Inflammatory bowel disease part- I: ulcerative colitis-pahophysiology and conventional and alternative treatment options. 2003, Volume 8, number 3, p. 247-283.
- Lindberg E, Tysk C, Andersson K, Jarnerot G. Smoking and inflammatory bowel disease: a case control study. Gut. 1998, 29:352-357.
- Sandborn WJ, Tremaine WJ, Offord KP, et al. Transdermal nicotine for mildly to moderately active ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997, 126:364-371.
- Kathleen A. Head, ND and Julie S. Jurenka, MT (ASCP), Alternative Medicine Review Inflammatory bowel disease part- I: ulcerative colitis- pahophysiology and conventional and alternative treatment options. 2003, Volume 8, number 3, p. 247-283.
- Barbara A. Hendrickson, Ranjana Gokhale, and Judy H. Cho, Clinical Aspects and Pathophysiology of Inflammatory Bowel Disease. Clinical Microbiology Reviews, Jan 2002, Vol. 15, No. 1 p. 79-94.
- Lashner BA. Recommendations for colorectal cancer screening in ulcerative colitis: a review of research from a single university-based surveillance program. Am J Gastroenterol. 1992, 87:168-75.
- Kwon JH, Keates S, Bassani L, Mayer LF, Keates AC. Colonic epithelial cells are a major site of macrophage inflammatory protein 3alpha (MIP-3alpha) production in normal colon and inflammatory bowel disease. Gut. 2002, 51:818-26. [PMID:12427784].
- Miner PB.Clinical features, course, laboratory findings, and complications in ulcerative colitis. In: Kirsner JB, ed. Inflammatory Bowel Disease. 5th ed. Philadelphia, Pa: WB Saunders Co; 2000, 299-304.
- Evaluation of Antidepressant Activity of Ailanthus excelsa roxb. Using Mice as Experimental Animal
Abstract Views :416 |
PDF Views:2
Authors
Affiliations
1 Department of Pharmacology and Toxicology Dharmsinh Desai University, College Road, Nadiad- 387001., IN
2 Dharmsinh Desai University, College Road, Nadiad- 387001, IN
3 Shree Swaminarayan College of Pharmacy, Village- Saij, NH-8, Kalol- 382721., IN
1 Department of Pharmacology and Toxicology Dharmsinh Desai University, College Road, Nadiad- 387001., IN
2 Dharmsinh Desai University, College Road, Nadiad- 387001, IN
3 Shree Swaminarayan College of Pharmacy, Village- Saij, NH-8, Kalol- 382721., IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 3, No 3 (2011), Pagination: 102-104Abstract
Introduction: Ailanthus excelsa Roxb. is a tree belonging to family Simaroubaceae, commonly known as a plant of Heaven. The bark of the plant is reported for various pharmacological activities including ear ache, aantimicrobial, anti-viral, antitumor, cytotoxic, hypotensive, abortifacient, diabetes mellitus, obesity and various uterine disorders in Ayurveda. Methanolic extract of Ailanthus excelsa (MeAe) in 150 mg/kg and 100 mg/kg doses are used for evaluation of antidepressant activity.
Objective: To evaluate antidepressant activity of Ailanthus excelsa Roxb. using mice as experimental animal by actophotometer and forced swim induced despair behaviour methods.
Methods: Swiss albino mice were randomly allocated to 4 groups (n=6); Group I (Normal Control), Group II (Standard group), group III and Group IV (Test Groups). Group I received distilled water while Group II, III and Group IV received Fluoxetine (10 mg/kg, i.p), MeAe 100 mg/kg and 150 mg/kg per oral respectively. Stem bark was extracted by cold maceration process. Antidepressant activity was estimated by actophotometer and forced swim induced despair behaviour methods.
Results: MeAe at dose of 150 mg/kg showed highly significant (p<0.01) increase in locomotion and decrease in immobility period while MeAe 100 mg/kg showed significant results in both methods.
Conclusion: MeAe (150 mg/kg and 100 mg/kg) has antidepressant activity in mice.
Keywords
Ailanthus excelsa Roxb., Antidepressant Activity, Actophotometer, Forced Swim Behaviour And MeAe.References
- Dhawan K, Dhavan S, Chhabra S. Attenuation of benzodiazepine dependence in mice by a trisubstituted benzoflavone moiety of Passiflora incarnate Linn. A non habit forming anxiolytic. J Pharm and Pharmceutical sciences 6(2): 2003; 215–222.
- Beaubrum G, Gray GE. A review of herbal medicines for psychiatric disorders. Psychiatr Service, 51; 2000:1130-1134.
- Evans WC. Trease and Evans Pharmacognosy. Harcourt Brace Elsevier, India. 2005.
- Anonymous, 1985. The Wealth of India, Raw Materials. Publication and information Directorate, New Delhi, pp: 116-118.
- Lavhale, M.S. and S.H. Mishra, 2007. Nutritional and therapeutic potential of Ailanthus excelsa: A review. Pharmacognosy Rev., 1: 105-113.
- Gülriz B, Ataa S, Ahmed F, Khaled R "Protein patterns and chemical constituents of Ailanthus altissima (Miller) Swingle and Ailanthus excelsa Roxb." IUFS J Biol, 67(1): 2008, 81-88.
- Kulkarni SK. Handbook of experimental pharmacology. Vallabh Prakashan, New Delhi, India; 1987.
- Garg R.and Gupta VB. Adaptogenic activity of milk and aqueous decoction of asparagus racemosus willd. In acute and chronic stress paradigms in mice. Journal of Cell and Tissue Research Vol. 10(2), 2010; 2281-2286.
- Porsolt RD., Anton G., Blaven N., Jalfre M.: Indian J Pharmacol, 47: 1978, 379-391.
- Rakotonirina VS, Bum EN, Rakotonirena A, Bopelet M. Sedative properties of the decoction of the rhizom of Cyperus anticulatives. Fitoterapia 2001; 72: 22–29.